Evidence map›Paper›PMID 38380709›Full record

ArticleAddiction biology2024

The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder.

Matthew L Banks, Jon E Sprague

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia, USA.
Jon E SpragueThe Ohio Attorney General's Center for the Future of Forensic Science, Bowling Green State University, Bowling Green, Ohio, USA.ORCID 0000-0003-0349-5072
Bowling Green State University · USVirginia Commonwealth University · US

Funding

VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI YAN ZHANG · 2014 to 2026
$13.8M
Mu Opioid Receptor Modulator Development to Treat Opioid Use DisorderUH3DA050311 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI ZHANG, YAN · 2023 to 2025
$4.3M
NIDA NIH HHS P30 DA033934NIDA NIH HHS P30DA033934NIDA NIH HHS UH3 DA050311NIDA NIH HHS UH3DA050311NIH HHS
6 · The paper itself

Abstract

Here, we present recent studies suggesting that specific DRD3 single nucleotide polymorphisms (SNPs, e.g. rs324029 and rs2654754) might serve as prognostic biomarkers for opioid use disorder (OUD). Additionally, preclinical studies with novel dopamine 3 receptor (D3R) partial agonists and antagonists have been evaluated as candidate OUD therapeutics and have shown a reduced risk of cardiovascular toxicity compared with the original D3R antagonist. From these findings, we argue that DRD3 SNPs could serve as a diagnostic tool for assessing OUD risk and that more research is warranted examining the D3R as a safe and effective therapeutic target for treating OUD.

Indexed as

Opioid-Related DisordersReceptors, DopamineAnalgesics, OpioidDopamineDopamine AgonistsDopamine AntagonistsHumansReceptors, Dopamine D3Analgesics, OpioidDopamineDopamine AgonistsDopamine AntagonistsReceptors, DopamineReceptors, Dopamine D3genetic riskopioidopioid use disorderpharmacogenetics

Identifiers

PMID38380709
PMCPMC10883601
OpenAlexW4391296458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.